Ratings by Guggenheim (Brad Canino )
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/28/2026 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2026 | Summit Therapeutics plc | SMMT | Maintain | Buy (N/A) |
|
Details | ||
| 7/20/2026 | AN2 Therapeutics | ANTX | New Coverage | Buy (N/A) |
4.67 (5.35) |
14.56% | Details | |
| 6/10/2026 | Nuvalent | NUVL | Downgrade | Neutral (Buy) |
123.25 (123.96) |
0.58% | Details | |
| 6/3/2026 | Celcuity Inc | CELC | Maintain | Buy (Buy) |
|
Details | ||
| 5/26/2026 | Relay Therapeutics | RLAY | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2026 | Bicara Therapeutics Inc | BCAX | New Coverage | Buy (N/A) |
23.09 (27.10) |
17.37% | Details | |
| 5/8/2026 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2026 | Celcuity Inc | CELC | Maintain | Buy (N/A) |
|
Details | ||
| 4/14/2026 | Tyra Biosciences | TYRA | New Coverage | Buy (N/A) |
35.62 (31.88) |
-10.5% | Details | |
| 3/17/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2026 | Relay Therapeutics | RLAY | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2026 | Janux Therapeutics | JANX | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2026 | Celcuity Inc | CELC | Maintain | Buy (N/A) |
|
Details | ||
| 2/17/2026 | Galecto | GLTO | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2026 | Cullinan Oncology Inc. | CGEM | New Coverage | Buy (N/A) |
11.92 (16.50) |
38.42% | Details | |
| 1/21/2026 | Crescent Biopharma Inc | CBIO | New Coverage | Buy (N/A) |
13.98 (14.47) |
3.51% | Details | |
| 12/8/2025 | Galecto | GLTO | Maintain | Buy (N/A) |
|
Details | ||
| 12/1/2025 | Galecto | GLTO | New Coverage | Buy (N/A) |
17.39 (28.69) |
64.98% | Details | |
| 11/20/2025 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2025 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
61.44 (103.40) |
68.29% | Details | |
| 10/8/2025 | CG Oncology | CGON | New Coverage | Buy (N/A) |
38.13 (71.19) |
86.7% | Details | |
| 10/8/2025 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
11.06 (11.45) |
3.53% | Details | |
| 9/22/2025 | Celcuity Inc | CELC | New Coverage | Buy (N/A) |
55.03 (86.38) |
56.97% | Details | |
| 9/4/2025 | ORIC Pharmaceuticals | ORIC | New Coverage | Buy (N/A) |
10.38 (11.07) |
6.65% | Details | |
| 9/4/2025 | Summit Therapeutics plc | SMMT | New Coverage | Buy (N/A) |
23.84 (13.02) |
-45.39% | Details | |
| 9/4/2025 | Janux Therapeutics | JANX | New Coverage | Buy (N/A) |
22.86 (15.17) |
-33.64% | Details | |
| 9/4/2025 | Relay Therapeutics | RLAY | New Coverage | Buy (N/A) |
3.66 (18.83) |
414.48% | Details | |
| 9/4/2025 | C4 Therapeutics | CCCC | New Coverage | Buy (N/A) |
2.51 (3.48) |
38.65% | Details |
